VBI Vaccines Inc/BC
Categories of dependency expected for this filer that were actually found stated in Risk Factors / MD&A.
- Filing
- 0001493152-24-014744 (10-K)
- Period
- 2023-01-01 to 2023-12-31
- XBRL tag
- us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Context
- From2023-01-01to2023-12-31
- Mapping
- seed · confidence 1.00
Extracted from Risk Factors / MD&A, checked verbatim against the source text before being stored.
“customer demand for our 3-antigen hepatitis B vaccine and pipeline candidates”
“the impact of competitive or alternative products, technologies, and pricing”
“our ability to retain and maintain a good relationship with our current employees, and our ability to competitively attract new employees with relevant experience and expertise;”
“the timing of, and our ability to, obtain and maintain regulatory approvals for our clinical trials, products, and pipeline candidates;”
“our ability to manufacture, or to have manufactured, our 3-antigen hepatitis B vaccine and our pipeline candidates, at a commercially viable scale to the standards and requirements of regulatory agencies;”
“the impact of the COVID-19 endemic and its effects on our clinical studies, research programs, manufacturing, business plan, regulatory review including site inspections, and the global economy;”
“the ability of our vendors and suppliers to manufacture and deliver materials in a timely manner that meet regulatory agency and our standards and requirements to meet planned timelines and milestones;”
“any disruption in the operations of our Rehovot, Israel manufacturing facility where we manufacture all of our clinical and commercial supplies of our 3-antigen hepatitis B vaccine and clinical supplies of our hepatitis B immunotherapeutic, VBI-2601;”